Systemically delivered statins can blunt airway inflammation in ovalbumin-challenged mice. However, in asthma clinical trials the beneficial effects of introducing oral statins are not compelling. We have invetigated this discrepancy using a clinically relevant murine model of allergic asthma, and by including a prophylactic study arm.
Introduction
Statins are competitive inhibitors of hydroxylmethylglutarylCoA reductase, the proximal rate-limiting enzyme of the mevalonate cascade. Beyond their capacity to block de novo cholesterol synthesis, statins inhibit formation of isoprenoid lipid chains that are needed for membrane anchorage and activation of signalling proteins that regulate cell proliferation, migration, contraction and secretory function (Kume, 2008; Zeki et al., 2009; Ghavami et al., 2011; Schaafsma et al., 2011b) . Thus, orally administered statins have pleiotropic systemic effects on endothelial function, platelet aggregation, and inflammation that enhance their therapeutic benefits on cardiovascular health (Ridker et al., 1998; Rosenson and Tangney, 1998) . Retrospective epidemiological investigation shows that long-term statin use can also be associated with health benefits for asthmatics; chiefly, reduced emergency room visits and corticosteroid use (Tse et al., 2013 (Tse et al., , 2014 . Some clinical evidence suggests that short-term statin use can enhance the anti-inflammatory effects of inhaled corticosteroids (Samson et al., 2006; Maneechotesuwan et al., 2010) . However, systematic review of clinical studies, which to date have not included prospective assessment of the prophylactic effects of long-term statin use, reveals a paucity of evidence for short-term oral statin therapy having a significant impact on lung function in asthmatics (Menzies et al., 2007; Hothersall et al., 2008; Cowan et al., 2010; Braganza et al., 2011; Malek Mohammad et al., 2012; Yuan et al., 2012) . This contrasts with results from preclinical studies showing that acute systemic statin therapy can prevent lung inflammation, and may reduce airway hyperreactivity in ovalbumin-sensitized rodents (McKay et al., 2004; Chiba et al., 2008a; Imamura et al., 2009; Zeki et al., 2009; Ahmad et al., 2011) .
Systemic delivery of simvastatin at the onset of ovalbumin administration in mice prevents airway inflammation by inhibiting lung leukocyte influx, promoting leukocyte apoptosis, and blunting biogenesis of pro-inflammatory cytokines and mediators (McKay et al., 2004; Luo et al., 2005; Imamura et al., 2009; Zeki et al., 2009) . Simvastatin treatment can also prevent ovalbumin exposure-induced airway goblet cell hyperplasia (Zeki et al., 2010) . In vitro studies indicate that statins can have direct effects on lung structural cells for example; simvastatin promotes apoptosis and inhibits proliferation of airway smooth muscle cells; blocks TGFβ 1 -induced extracellular matrix protein production by airway fibroblasts and airway smooth muscle cells; and, blocks cytokine release by airway epithelial cells (Takeda et al., 2006; Ghavami et al., 2011; Schaafsma et al., 2011a,b; Zeki et al., 2012) . Despite focus on the effects of statins on lung inflammation and remodelling, there is more limited investigation of airway hyperresponsiveness, a characteristic of asthma. Lovastatin appears to reduce contractility of bronchi isolated from ovalbumin challenged rodents (Chiba et al., 2008a,b) . Systemic simvastatin treatment reportedly prevents increased lung resistance in ovalbumin exposed mice (Zeki et al., 2009; Ahmad et al., 2011) Recent pre-clinical studies in mice suggest that inhaled statins may affect lung function (Wu et al., 2017) , but delivery of statins to the lungs is not approved for humans. Real world interpretation and translation of results from pre-clinical studies of systemically delivered statins is limited as none have investigated the effects of long-term, prophylactic treatment or monitored the concentration of statins that accumulate in the lung; and, all used ovalbumin as an aeroallergen (Johnson et al., 2004; Johnson et al., 2008; Gregory and Lloyd, 2011) .
The current study compares the effects of prophylactic and acute systemic simvastatin therapy on lung inflammation, airway goblet cell remodelling, and airway function in a murine model of allergic asthma that is induced by repeated lung challenge with house dust mite (HDM). We have monitored pharmacokinetics and accumulation of simvastatin in serum, lung tissue and lung lavage. We found that repeated systemic delivery of simvastatin resulted in its accumulation in serum, but not in the lungs. Prophylactic systemic delivery of simvastatin increased anti-inflammatory effects, however, consistent with clinical studies, systemic simvastatin had no effect on airway hyperreactivity.
Methods

Simvastatin formulation
Simvastatin was prepared as described by McKay et al. (McKay et al., 2004) , by adding 150 μL of 0.1 N NaOH to 100μL simvastatin stock solution (40 mg mL À1 in ethanol), incubating at 50°C for 2 h and then, after adjusting to pH 7.0, diluting to 1 mL with phosphate buffered saline (PBS) (final concentration 4 mg mL À1 simvastatin).
House dust mite challenge and simvastatin treatment protocols
All animal care and experimental procedures were carried out according to protocols approved by the University of Manitoba animal ethics committee. We obtained female Balb/c mice (6-8 weeks old) from the Central Animal Care Facility at University of Manitoba and maintained in 12-hour light/dark cycles with access to food and water ad libitum in individually ventilated cages. Each mouse was assigned an identity number and randomized to different groups so that all experiments were carried out in a blinded manner. Mice were housed in groups of 3 per cage. Animals were killed at experimental end points by overdose of pentobarbital sodium, given i.p. Female Balb/c mice are commonly used to study asthma in-vivo (McKay et al., 2004; Kim et al., 2007) . Mice were challenged with house dust mice (HDM) Dermatophagoides farina (Greer Labs, Lenoir, NC) by repeated exposure as we have previously described (Anaparti et al., 2016; Piyadasa et al., 2016) . The stock solution for the lot of HDM used for this study included 137.9μg Der P1 mL À1 and 132.2 endotoxin units of lipopolysaccharide mL À1 . HDM dissolved in saline was delivered by intranasal instillation (35μL; 0.75 μg HDM μL À1 ) in mice sedated with isoflurane (5%). Animals were challenged daily for 5 consecutive days, followed by 2 days "rest", and then another 5 consecutive days of HDM challenge. For an allergen naïve control, age-matched mice were challenged with intranasal saline only. Simvastatin was administered to the animals by s.c. injections, to bypass the hepatic first pass metabolism responsible for low bioavailability of simvastatin. Animals were treated with one of two protocols: 1)
for acute treatment, mice received simvastatin s.c. (40 mg kg À1 ) concomitantly with each HDM or saline-only i.n. challenge; and 2) for prophylactic treatment, mice received 3 s.c. injections of simvastatin every other day, over 5 days, in the week prior to undergoing the acute HDM challenge and simvastatin treatment protocol ( Figure 1A ). We developed the prophylactic experimental arm in an effort to mimic retrospective clinical data that suggest statin use indicated for non-respiratory disease reasons has consistently been associated with reduced asthma exacerbations and ER visits (Tse et al., 2013; Tse et al., 2014) . The duration used for prophylactic treatment was determined in pilot experiments and our previous studies that revealed maximum steady-state concentrations of serum simvastatin, measured using ultrahigh performance liquid chromatography-tandem mass spectrometry (UHPLC/MS/ MS), are reached within one week, thus longer periods of pre-treatment were not necessary (Bews et al., 2014) . Each time point and experimental, treatment and control group included 9 mice. The sample size, n = 6, was estimated based on the power (0.95) calculation performed (G*Power 3.1) using preliminary data for the primary end point (airway resistance, R N ) for allergen naïve and HDM-challenged animals. An additional 3 animals in each group were also required for complementary histological indexing. Mice were studied 8 or 48 h after final challenge: being subjected to lung function testing, and collection of bronchoalveolar lavage fluid (BALF), blood and lung tissue for assessing inflammation and tissue histology.
Simvastatin measurement and pharmacokinetics
To determine the accumulation of pharmacologically active simvastatin in serum, BALF and lung homogenates from mice in acute treatment and prophylactic treatment groups, we used our established extraction and UHPLC/MS/MS protocol for the simultaneous measurement of simvastatin and pharmacologically active simvastatin-hydroxy acid (Bews et al., 2014) . Notably, this protocol is unique in that it decreases the spontaneous conversion of simvastatin to simvastatinhydroxy acid that can occur during processing by minimizing the time the compound is in aqueous solution and by buffering samples to physiological pH; this preserves the endogenous abundance of pharmacologically active simvastatin in biosamples. In brief, samples were prepared via solid phase extraction, with methanol elution, then dried and reconstituted in 80:20 (v/v) acetonitrile:sodium phosphate monobasic (pH 7.4) just prior to analysis using an Agilent (Mississauga, ON) 1200 ultrahigh performance liquid chromatograph coupled to a 6410B triple quadrupole mass spectrometer with electrospray ionization in positive mode. The column used was an Agilent Zorbax C18 column 
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(2.1 mm × 50 mm × 1.8 μm dp). Using this method, the lower limit of quantitation for simvastatin was 0.16 ng mL À1 and for simvastatin-hydroxy acid, the limit was 8.3 ng mL À1 .
Pharmacokinetic study. In an independent study, 8-week old, female Balb/c mice received a single s.c. injection of simvastatin (40 mg kg À1 ). Animals were anaesthetised using sodium pentobarbital, 90 mg kg À1 (i.p.) prior to collecting blood (cardiac puncture) and lungs at 8, 16, 32 and 48 h. Three mice were investigated at each time point, including just prior to simvastatin administration (0 h). Serum was separated from blood samples using centrifugation (2300× g, 10 min, room temperature) prior to storage. Lungs were excised, rinsed in ice cold PBS and stored at À80°C until being subjected to Polytron homogenization in 500μL lysis buffer (composition: 10 mM Tris pH 7.5, 150 mM NaCl, 1:100 NP40, 1 g per 100 mL deoxycholic acid salt, 0.1% SDS, 1:100 protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO), 1:100 phosphatase inhibitor cocktail 2 (SigmaAldrich), and 1 mM PMSF, pH adjusted to 8.0). After centrifugation (2300 x g, 15 min, 4°C) samples were briefly stored (À80°C) prior to analysis by UHPLC/MS/MS.
Inflammatory cell counting
As previously described (Ryu et al., 2014) , immediately after lung function testing, mouse lungs in situ were lavaged twice with 1 mL ice cold saline. BALF was centrifuged (100 x g for 10 min) to pellet cells, which were re-suspended in in 1 mL saline prior to determining total cell count using a haemocytometer. For differential cell counting, cytospin preparations of suspended BALF cells were air dried and stained with modified Wright-Giemsa stain (HEMA 3 STAT PACK; Fisher Scientific, Waltham, MA). Cell number and differential analysis was performed manually, identifying eosinophils, lymphocytes, macrophages, and neutrophils in six randomly chosen fields examined with a light microscope at 200X magnification. Average cell count was used to calculate the absolute cell numbers normalized to BALF volume. An experienced technician who was blinded to the sample group identity performed the cell counting.
Cytokine assay
We quantified a panel of 10 cytokines and chemokines in duplicate in BALF supernatant, using the V-PLEX 
Lung histology
Lungs were collected from mice that were not subjected to lung function testing or BALF collection. In situ, a polyethylene tracheal cannula was inserted by tracheostomy then lungs were carefully removed from the chest cavity and both inflated (1 mL 10% formalin) and submerged in 10% formalin for 24 h. The left lobe of the lung was excised then subjected to serial alcohol dehydration prior to embedding in paraffin wax. Sections (6 μm thick) were cut using a microtome along the longitudinal axis to the midline of the lobe then subjected to periodic acid Schiff (PAS) staining to identify airway goblet cells. Images of stained sections were obtained by an upright Olympus light microscope equipped with SPOT CCD camera and Image Pro Plus Software. To quantify goblet cells, the basement membrane was traced using manual tracing tool and the perimeter of the basement membrane was converted from pixel to μm (30pixels per μm) and then using colour segmentation the number of goblet cell was calculated. Only airways of similar perimeter were included in the analysis.
Lung function testing
As previously described (Ma et al., 2007; Ryu et al., 2014; Piyadasa et al., 2016) , lung function of anaesthetised mice (i.p. sodium pentobarbital, 90 mg kg À1 ) tracheostomised with a 20-gauge polyethylene catheter was measured using a flexiVent ventilator (Scireq Inc. Montreal, PQ). Mice were ventilated at 2.5 Hz using a tidal volume of 10 ml kg À1 , and 3 cmH 2 O positive end expiratory pressure (PEEP) Mice were subjected to increasing concentrations (0-50 mg mL À1 ) of nebulized methacholine (MCh) via an in-line ultrasonic nebulizer, to assess respiratory mechanics. Changes in respiratory mechanics were assessed by low frequency forced oscillation, normalized to body weight. Respiratory mechanical input impedance (Zrs) was derived from the displacement of the ventilator's piston and the pressure in its cylinder. Corrections for gas compressibility, and resistive and accelerative losses in ventilator, tubing and catheter were applied according to the manufacturer's instructions. Zrs was fitted to a constant phase model to extrapolate Newtonian resistance (R N ) (an index of conducting airway resistance), peripheral tissue and airway resistance (G), and lung stiffness (H). Values were calculated as the mean of 20 perturbation cycles performed after each MCh challenge. A fall in FEV 1 by 20% in response to MCh challenge (PC 20 ) is equivalent to 43.5% rise in respiratory resistance (Short et al., 2015) . In our model, the MCh PC 20 was calculated assessing the MCh concentration required to increase R N by 43.5% from the base.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Data are presented as mean values ± SEM. Means were compared by univariate or oneway ANOVA and Tukey multiple comparisons test, using SPSS_20 software (IBM Canada Ltd., Markham, ON). A Pvalue <0.05 was used to define statistically significant differences between mean values. The univariate analysis, we performed for analysing the lung function data using SPSS, is a two-way ANOVA that incorporates a nested variable, methacholine dose, because it is not a completely independent variable.
Materials
The compounds used here were provided by the following suppliers: simvastatin by Toronto Research Chemicals (Toronto, ON, Canada); methacholine by Sigma-Aldrich, USA.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b) .
Results
Simvastatin pharmacokinetics
The peak serum concentration of pharmacologically active simvastatin hydroxy acid was reached 8 h after a single s.c. administration of simvastatin (40 mg kg À1 ); this declined sharply 16 and 32 h post-administration and, 48 h after a single s.c. injection, was no longer detectable ( Figure 1B) . Levels of simvastatin hydroxy acid were below the level of detection in lung tissue and BALF at all time points. Having established the kinetics of single dose simvastatin, we next measured the levels of pharmacologically active simvastatin at experimental endpoints for both the acute and prophylactic treatment regimens. Eight hours after the final administration of simvastatin, serum concentration was about 50 μg L À1 in animals receiving acute treatment, and this was more than doubled in animals that received prophylactic treatment ( Figure 1C ). In this study, we used only three animals (n = 3), as we calculated power to be >0.95, using α = 0.05 to predict significant differences among groups. On this basis, and to implement the 3Rs (reduce, refine, replace) for animal research we restricted the number of biological replicates to three. Both treatment regimens established a similar steady state concentration of simvastatin in the systemic circulation, measured 48 h after final administration. This suggests that serum simvastatin hydroxy acid concentration follows a dynamic pattern after each s.c. administration, and with repeated treatment establishes stable levels in the systemic circulation. In striking contrast, neither the acute nor the prophylactic treatment protocol was sufficient to establish levels of simvastatin hydroxy acid within the limits of quantitation for UHPLC/MS/MS of lung tissue or BALF.
Inflammatory cell count 8-hours post-HDM challenge. Lung influx of inflammatory cells was induced markedly by HDM challenge, compared to the allergen naïve mice (Figure 2A ). Acute treatment with simvastatin significantly blunted HDM challenge-induced inflammatory cell number in BALF by approximately 25%. Prophylactic simvastatin treatment significantly prevented HDM challenge-induced total inflammatory cell influx by 70%, an inhibitory effect that was significantly greater and nearly twice that achieved with the acute treatment protocol. HDM challenge induced pronounced lung neutrophilia and acute treatment with simvastatin was not sufficient to significantly inhibit neutrophil accumulation. However, prophylactic treatment did significantly decrease neutrophil accumulation in BALF by 77%. HDM challengeinduced eosinophilia was not reduced by acute treatment, however eosinophil accumulation was significantly inhibited by 78% with prophylactic treatment. Neither acute nor prophylactic treatment was sufficient to change the number of macrophages/monocytes after HDM challenge, whereas prophylactic (but not acute) simvastatin treatment significantly inhibited HDM-induced lung lymphocyte influx by over 75%.
48 hours post-HDM challenge. HDM challenge-induced lung inflammatory cell accumulation in BALF was sustained for 48 h beyond final allergen exposure ( Figure 2B ). Both acute simvastatin treatment and prophylactic treatment prevented HDM-induced total lung leukocyte infiltration. At this time, in HDM-challenged mice, eosinophils were the predominant cell type in BALF. Of note, eosinophil accumulation was significantly reduced by 55% with acute simvastatin treatment and even more so by prophylactic treatment which reduced eosinophil number by nearly 85%. Lung neutrophilia persisted 48 h after HDM challenge and this was blunted significantly by prophylactic treatment but not by the acute treatment regime. As we observed 8 h post-allergen challenge, neither acute nor prophylactic treatment was sufficient to limit the number of macrophages/monocytes 48 h after HDM challenge, whereas prophylactic (but not acute) simvastatin treatment significantly inhibited HDM-induced lung lymphocyte influx by 61%.
Cytokine analysis
As the profile of leukocytes in BALF was different 8 and 48 h after HDM challenge, being predominantly neutrophilic and eosinophilic, respectively, we profiled a panel of 10 proinflammatory cytokines and chemokines in BALF at both experimental end points.
8-hours post-HDM challenge. Compared to allergen naïve mice, HDM challenge induced significant accumulation of a number of mediators, including: a 100-fold rise in TNFα; 45-fold increase in CXCL1; 300-fold higher IL-6 levels; 190-fold increase in IL-4; 240-fold increase in IL-5; 800-fold rise in IFN-γ; and, 80-fold accumulation of IL-1β ( Figure 3A ). Neither IL-2 nor IL-12 were detected in BALF from naïve mice. However, following the HDM challenge, levels of IL-2 were increased to 5.2 ± 1.1 pg mL À1 and those of IL-12 to almost 20 pg mL À1 ( Figure 3A ). Both acute and prophylactic simvastatin treatment protocols inhibited HDM challengeinduced accumulation of a number of pro-inflammatory cytokines by 60-95%, including TNFα, CXCL1, IL-6, IL-4, IL-1β, and IFN-γ. The level of IL-12 in BALF was also reduced to below detection limits by both treatment protocols. In contrast, neither acute nor prophylactic treatment affected HDM challenge-induced IL-2 (data not shown). Notably, though acute treatment had no significant effect on IL-5 in BALF from HDM challenged mice, prophylactic treatment significantly inhibited IL-5 level by 95%. Interestingly, for the anti-inflammatory cytokine, IL-10, acute and prophylactic simvastatin treatment suppressed HDM challenge-induced accumulation in BALF by 84.6 ± 6.9% and 94.5 ± 1.4%, respectively.
48-hours post-HDM challenge. As shown in Figure 3B , as we observed 8 h after HDM challenge, and compared to naïve BJP A Jha et al.
Figure 2
Effects of HDM challenge and acute and prophylactic simvastatin treatment on leukocyte number and differential counts in BALF. Cell counts determined A) 8 h and B) 48 h after completing HDM challenge, with and without simvastatin treatment. For all data, cell number is normalized to initial BALF volume and presented as mean ± SEM from 6 animals per group. *P < 0.05, significantly different as indicated; one-way ANOVA with Tukey's multiple comparison test.
mice, 48 h after allergen exposure we measured significant elevation in four pro-inflammatory cytokines in BALF, including: 23-fold rise in IL-1β; 7-fold accumulation of IL-4; 38-fold increase in IL-5; and, 6-fold rise in CXCL1. There was also, at this time, a 7-fold increase in the antiinflammatory cytokine, IL-10 ( Figure 3B ). Conversely, though a trend for elevated levels was apparent, we did not observe a statistically significant change in the abundance of IFN-γ, IL-12, IL-2, IL-6 or TNFα compared to allergen naïve animals (data not shown). Acute and prophylactic treatment with simvastatin prevented HDM challengeinduced accumulation of IL-1β by 70% and 85%, respectively. Notably, prophylactic simvastatin treatment, but not the acute therapy regimen, markedly reduced the HDM-induced increase of IL-4, IL-5 and by over 75%, and prophylactic treatment was significantly more effective that acute treatment in damping allergen challenge-associated accumulation of the Th2-cytokine, IL-4, and the proneutrophilic chemokine, CXCL1. In contrast to the effects we measured 8 h after allergen challenge, only prophylactic,
Figure 3
Effects of HDM challenge and acute and prophylactic simvastatin treatment on cytokine accumulation in BALF. Cytokine abundance determined by 10-plex MSD array A) 8 h and B) 48 h after completing HDM challenge with and without simvastatin treatment. For all data, cell number is normalized to initial BALF volume and presented as mean ± SEM from 6 animals per group. *P < 0.05, significantly different as indicated; oneway ANOVA with Tukey's multiple comparison test.
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and not acute, simvastatin treatment decreased the levels of anti-inflammatory IL-10 in BALF 48 h after allergen exposure.
Lung histology
Lung histology was performed to assess airway goblet cell hyperplasia using PAS staining and quantitative microscopy. Goblet cells were absent in peripheral airways of allergen naïve animals (mean airway perimeter, 161± 28.5 μm; n = 3 animals per group and at least 9 airways from each animal were analysed). In contrast, in similar sized airways, both 8 and 48 h after completing allergen challenge, robust goblet cell staining per unit of basement membrane was evident (Figure 4 ). Both acute and prophylactic simvastatin treatment were sufficient to virtually abolish the development of goblet cell hyperplasia after allergen challenge. As lung histology analysis was complementary to the other parameters studied, biological replicates were kept at n = 3, which still ensured power > 0.95, using α = 0.05 to predict significant differences among groups, and to implement 3R policy to reduce animal use in research.
Lung function
We used a small animal ventilator to measure airway reactivity to inhaled MCh, 8 and 48 h after completing the HDM exposure protocol. Consistent with our earlier studies (Ryu et al., 2014; Piyadasa et al., 2016) , airway resistance (R N ) was not different from that in allergen naïve animals at the 8 h experimental end point, but 48 h after the final HDM challenge, we observed a significant increase in R N in response to 25 and 50 mg mL À1 MCh ( Figure 5A ). Therefore, we only assessed the effects of acute and prophyactic simvastatin treatment on lung function 48 h after completing HDM challenge. In contrast the inhibitory effects of simvastatin therapy on allergen-induced lung inflammation and goblet cell hyperplasia, neither acute nor prophylactic simvastatin treatment prevented airway hyperreactivity -increased R N -48 h after HDM exposure ( Figure 5A ). Similarly, simvastatin therapy was without effect on increased lung elastance (H) caused by allergen challenge ( Figure 5B) . Tissue damping (G) -an indicator of the combined contribution of small airways resistance and lung elastic recoil -was increased after HDM challenge, but this effect was blunted significantly by both acute and prophylactic simvastatin treatment when mice were exposed to high concentrations of MCh ( Figure 5C ). In line with the hyperreactivity, HDM challenge significantly induced hypersensitivity to MCh (PC 20 for HDM challenged mice was 3.2±2.2 mg mL À1 compared 25.2±4.5 mg mL À1 for naïve mice) that remained unchanged by both acute and prophylactic treatment with simvastatin.
Discussion
This study addresses a lack of full concordance of results for the effects of systemically delivered statins on asthma pathophysiology from pre-clinical, small animal model studies and human clinical trials. With a murine model of allergic asthma that is induced by repeated delivery to the lungs of a clinically relevant aero-allergen, HDM, for asthma (Gregory and Lloyd, 2011; Desai and Brightling, 2012) , we showed that acute systemic delivery of simvastatin in parallel with allergen challenge blocked more than 50% of allergic inflammation in the lung -including eosinophil and neutrophil influx, and
Figure 5
Effects of HDM challenge and acute and prophylactic simvastatin treatment on respiratory mechanics. Lung function was assessed using a flexiVent small animal ventilator 48 h after completing HDM challenge with and without simvastatin treatment. A) Newtonian resistance (R N ), B) tissue elastance (H) and C) tissue resistance (G) were measured in response to sequential challenge with nebulized saline (0) or MCh (3-50 mg/mL). Data are presented as mean ± SEM from 6 animals per group. Comparisons of naïve and each treatment were performed against HDM challenge: *P < 0.05, significantly different from corresponding HDM value; Univariate analysis followed by Tukey multiple comparison test.
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pro-inflammatory cytokine release -as well as abolishing airway goblet cell hyperplasia. Moreover, prophylactic simvastatin treatment, which establishes sustained levels of pharmacologically active simvastatin in the blood, blunts all indices of allergic lung inflammation even more effectively than acute treatment, and abolished airway goblet cell hyperplasia. Despite the marked inhibitory effects of acute or prophylactic systemic simvastatin therapy on the measures of lung inflammation, they were without effect on airway hyperreactivity, a characteristic feature of asthma. These findings also indicated that, with systemic delivery, pharmacologically active simvastatin did not accumulate in the lungs, indicating that beneficial effects to prevent lung inflammation were more likely to be associated with a mechanism of action in the systemic circulation and on the behaviour of circulating leukocytes. Though the pharmacodynamics of oral statin therapy has been described in humans (US FDA, 2015) , for lung diseases it has not been a primary point of assessment for systemically delivered statins in pre-clinical studies. We found that serum simvastatin concentration increased sharply after s.c. delivery, but this declined rapidly for a single administration and was not detectable 48 hours later. This is consistent with human pharmacokinetic trials that show peak plasma concentrations within 4 hours of oral simvastatin therapy, and that this is reduced to only 10% of the peak concentration 8 hours later (FDA, 2015) . A caveat of our study is that we did not measure peak simvastatin hydroxyl acid until 8 hours after treatment, thus we may not have determined the maximum peak that could have been attained. Nonetheless, we did use our previously established UHPLC/MS/MS protocol that is tuned to specifically monitor pharmacologically active simvastatin hydroxy acid (Bews et al., 2014) to show that prophylactic treatment established a steady-state serum concentration of simvastatin hydroxy acid~50μg L À1 . Similar circulating levels of pharmacologically active simvastatin were also likely to have been achieved with acute treatment in parallel with HDM challenge. Notably we show that peak levels of active simvastatin 8 hours after drug delivery were more than doubled, >120 μg L À1 , with the prophylactic treatment protocol. The different peak level of circulating, pharmacologically active simvastatin that is achieved by prophylactic therapy, combined with the kinetics of circulating simvastatin hydroxy acid that we describe, is an important factor in elucidating the possible mechanisms for the effects of simvastatin on the evolution of lung inflammation in HDM-challenged mice. Our findings are consistent with a number of studies that show the systemic delivery of statins is associated with decreased influx of inflammatory cells and goblet cell hyperplasia, after allergen challenge (McKay et al., 2004; Kim et al., 2007; Imamura et al., 2009; Zeki et al., 2009) . These earlier studies used mice subjected to ovalbumin sensitization and challenge to induce eosinophilic lung inflammation, thus the primary benefit of statin therapy is reported to be the prevention of lung eosinophilia and eosinophil-associated cytokines such as IL-5 and eotaxin-1 (McKay et al., 2004; Zeki et al., 2009 Zeki et al., , 2012 . The HDM-challenge model uses aeroexposure to a complex allergen that includes many different antigenic peptides, some with proteolytic activity to induce inflammation (Johnson et al., 2004) . We observed overlapping neutrophil, eosinophil, macrophage/monocyte and lymphocyte accumulation in the lung. This includes an early peak in neutrophil accumulation (8 hours post allergen) and a later peak in eosinophil accumulation (48 hours post allergen). Therefore, our experiments can separate the effects of simvastatin therapy on different immune cell types. Prophylactic simvastatin treatment is significantly more effective than acute treatment in suppressing neutrophil, eosinophil and lymphocyte recruitment to the lungs at all experimental end points. Indeed, acute simvastatin therapy was ineffective in controlling the neutrophilia observed with HDM challenge. The differential effects of prophylactic treatment could be attributed to the higher serum concentration of simvastatin hydroxy acid. This is consistent with previous observations by McKay et al. (2004) who reported that only high doses of simvastatin, given i.p., induced a histological reduction in inflammatory infiltrates in the lungs, an effect that may be linked to processes that involve vascular cell adhesion and interstitial cell adhesion molecules (McKay et al., 2004; Kim et al., 2007) . In line with these studies, Zeki et al. (2015) demonstrated that intra-tracheal instillation of pravastatin, which is retained in the lung and does not accumulate significantly in plasma, was not sufficient to reduce BALF total leukocyte or eosinophil cell count in ovalbumin-exposed mice. Collectively, our observations support a general concentration-dependent role for simvastatin hydroxy acid in the circulation to disrupt the influx and accumulation of inflammatory cells in the lung in response to allergen challenge.
In line with previous reports using ovalbumin challenged mice, we showed that either acute or prophylactic simvastatin treatment was sufficient to prevent goblet cell hyperplasia (McKay et al., 2004; Zeki et al., 2009; Zhu et al., 2012) . This effect is likely to be attributable to our findings that simvastatin therapy inhibited eosinophil infiltration and the associated release of mediators that promote mucus production (McBrien and Menzies-Gow, 2017) .
To complement our studies comparing the magnitude of the effect of acute and prophylactic simvastatin therapy on lung inflammatory cell influx and goblet cell hyperplasia, we also used 10-plex technology for quantitative profiling of pro-and anti-inflammatory cytokines and chemokines in BALF. Consistent with HDM-associated human asthma (Gregory and Lloyd, 2011; Desai and Brightling, 2012) HDM challenge in animals induced a complex inflammatory response, increasing pro-inflammatory cytokines that support eosinophilic and neutrophil inflammation, Th1-and Th2-like responses, as well as the anti-inflammatory cytokine, IL-10. As reported in earlier studies using ovalbumin-exposed mice (McKay et al., 2004; Imamura et al., 2009; Zeki et al., 2009 Zeki et al., , 2012 , we also observed a broad inhibitory effect of systemic simvastatin therapy on cytokine accumulation in the lungs. This was most evident at 8 hours after HDM challenge when a broader spectrum of cytokines and chemokines (IFNγ, and TNFα) were present and were inhibited by both acute and prophylactic therapy:. We found that only prophylactic simvastatin therapy prevented lung neutrophilia and this effect was mirrored by the inhibition of CXCL1 accumulation in BALF 8 and 48 hours after HDM challenge. Similarly, pro-eosinophilic IL-5 and IL-4 in BALF were inhibited by prophylactic simvastatin therapy 8 and 48 hours after allergen challenge, a pattern that appeared to be mirrored by acute treatment, though the trend for the latter was not statistically significant. Interestingly, prophylactic treatment prevented the accumulation of anti-inflammatory IL-10 and the stereotypic Th2 cytokine, IL-4, 8 and 48 hours after HDM challenge but acute simvastatin therapy only slowed their accumulation as peak allergen-induced levels were still reached 48 hours after HDM challenge. This is inconsistent with some reports that simvastatin can upregulate IL-10 in human subjects with chronic obstructive lung disease (Maneechotesuwan et al., 2015) . A limitation of our experiments is that though we observed a suppression of lymphocyte influx with simvastatin therapy, our cytokine array did not include IL-17, which is downregulated by statin treatment in ovalbumin-primed mice (Imamura et al., 2009; Wu et al., 2017) . Changes in IL-17 levels could have shed light on the effects of therapy on Th17 / Treg cell balance as a mechanism for Treg-associated suppression of Th2 cell-mediated inflammation. To overcome these limitations we are incorporating broader cytokine arrays in our ongoing and future work. Overall our data indicate that in parallel with inhibitory effects on inflammatory cell influx, compared to acute simvastatin treatment, prophylactic therapy more effectively suppresses the breadth and magnitude of the cytokine and chemokine milieu that develops in the lung with repeated HDM challenge.
A principal goal of any asthma therapy is to improve lung function by mitigating the debilitating tendency for paroxysmal bronchial spasm associated with airway hyperresponsiveness. In vivo, preclinical studies by Zeki et al. (2009) show that systemically delivered simvastatin modified ovalbumin exposure-induced, increased respiratory resistance at baseline and in response to low concentration inhaled MCh. In a chronic ovalbumin challenge model of airway remodelling, but with low levels of lung inflammatory cell infiltrate, simvastatin treatment improved indices of lung and airway resistance (Ahmad et al., 2011) . There is a general lack of concordance of such studies with clinical trials in asthmatics, which have not revealed any substantive improvement in airway function resulting from oral statin therapy. Indeed one study suggests statin treatment may lead to a decline in the forced expiratory volume in 1 second (FEV 1 ) (Ostroukhova et al., 2009) , while others show no effects of statin treatment on lung function (Hothersall et al., 2008; Braganza et al., 2011; Moini et al., 2012; Yuan et al., 2012) . One randomized controlled trial did report that in a subgroup of asthmatics that can tolerate withdrawal of inhaled corticosteroid therapy, oral simvastatin (40 mg per day) showed a 150 mL improvement in pre-bronchodilator FEV 1 (Cowan et al., 2010) . For the current study we used a repeat HDM challenge protocol to mimic the complex inflammatory and tissue remodelling microenvironment associated with human allergic asthma. Although we showed that acute and prophylactic systemic treatment with simvastatin diminished lung inflammation, neither mode was enough to prevent increased respiratory resistance, central airway resistance (RN) -which accounts for 80% of total respiratory resistance -or lung elastance (H) in HDM challenged mice. Interestingly, similar to published data (Ahmad et al., 2011) , at the highest concentration of MCh challenge, both acute and prophylactic simvastatin did significantly inhibit the HDM-induced increase in alveolar tissue constriction (G). This index of lung function reflects small airway function, as well as lung parenchymal tissue changes associated with edema and inflammatory cell influx. Thus, our demonstration of a protective effect of systemic simvastatin therapy on G is consistent with the fact that lung inflammation is also significantly reduced.
Despite effects of systemic simvastatin therapy on peripheral lung damping induced by high dose MCh, our findings reveal this is not sufficient to manifest as an improvement in respiratory resistance. The failure for systemic simvastatin to significantly improve airway resistance in HDM challenged mice is consistent with results of human clinical trials for oral statin therapy in asthma, as clinical indices for airway conductance, such as FEV 1 , are not improved (Silva et al., 2012) . Our pharmacokinetic data suggest that the refractory nature of airway hyperreactivity to systemically administered simvastatin may be associated with the failure of its pharmacologically active form to accumulate in the lungs, thereby preventing direct or sustained effects on resident epithelium, smooth muscle and other structural cells. The absence of simvastatin or its hydroxy acid form in the lungs may be due, in part, to its lipophilicity that likely favours deposition in lipid rich organs, thus compromising already-low bioavailability <5% (US FDA, 2015) . Despite this we did expect that some circulating simvastatin would reach to the lungs through the bronchial circulation. However, as the bronchial circulation receives only a fraction of the cardiac output, it is likely that the amounts of simvastatin reaching the lungs by this route are very small. Another mechanism for limiting accumulation of simvastatin is the presence of the simvastatin metabolizing enzyme, CYP3A11 in mouse lung (CYP3A4 in humans) (Haag et al., 2003; Biggs et al., 2007; Li et al., 2009; Shah et al., 2011) . Recent evidence indicates that direct delivery of statins to the lung may be needed to reverse airway hyperreactivity and hypersensitivity (Zeki et al., 2015; Wu et al., 2017) . Thus our evidence indicated that systemic administration of simvastatin was not able to mitigate airway dysfunction, despite its capacity to prevent immune cell influx and release of proinflammatory cytokines.
In summary, using a murine model of allergic asthma that employs repeated challenge with the clinically relevant aero-allergen, HDM, we have demonstrated that systemic delivery of simvastatin was sufficient to inhibit lung infiltration by inflammatory cells, and release of Th1 and Th2 cytokines. Moreover, prophylactic treatment that established a steady state circulating concentration of simvastatin hydroxy acid prior to allergen challenge was more effective than commencing treatment at the onset of allergic insult. In a manner that parallels human clinical trials, we confirmed that systemic delivery of simvastatin, acutely or prophylactically, was without effect on allergen challengeinduced airway hyperreactivity. Our findings support the need for developing approaches for the delivery of statins directly to the lung, perhaps in concert with systemic delivery, to assess the real potential of this therapeutic approach for asthma control.
